参考文献
[1] Hockham C, Bao L, Tiku A, et al. Sex differences in chronic kidney disease prevalence in Asia: a systematic review and meta-analysis[J]. Clin Kidney J, 2022,15(6):1144-1151.
[2] Younes S, Mourad N, Safwan J, et al. Chronic kidney disease awareness among the general population: tool validation and knowledge assessment in a developing country[J]. BMC Nephrol, 2022,23(1):266.
[3] Zhan Y, He X, Hong D, et al. The current status of chronic kidney disease-mineral and bone disorder management in China[J]. Sci Rep, 2022,12(1):16694.
[4] Zhao X, Niu Q, Gan L, et al. Baseline data report of the China Dialysis Outcomes and Practice Patterns Study (DOPPS). Sci Rep. 2021;11(1):873..
[5] Kobayashi S. Cardiovascular Events in Hemodialysis Patients: Challenging against Vascular Calcification[J]. Ann Vasc Dis, 2017,10(1):1-7.
[6] Moe S M. Current issues in the management of secondary hyperparathyroidism and bone disease[J]. Perit Dial Int, 2001,21 Suppl 3:S241-S246.
[7] Eddington H, Hoefield R, Sinha S, et al. Serum phosphate and mortality in patients with chronic kidney disease[J]. Clin J Am Soc Nephrol, 2010,5(12):2251-2257.
[8] Clarke B L, Brown E M, Collins M T, et al. Epidemiology and Diagnosis of Hypoparathyroidism[J]. J Clin Endocrinol Metab, 2016,101(6):2284-2299.
[9] Lin W, Li Y, Chen F, et al. Klotho preservation via histone deacetylase inhibition attenuates chronic kidney disease-associated bone injury in mice[J]. Sci Rep, 2017,7:46195.
[10] Naveh-Many T, Volovelsky O. Parathyroid Cell Proliferation in Secondary Hyperparathyroidism of Chronic Kidney Disease[J]. Int J Mol Sci, 2020,21(12).
[11] Ritter C S, Pande S, Krits I, et al. Destabilization of parathyroid hormone mRNA by extracellular Ca2+ and the calcimimetic R-568 in parathyroid cells: role of cytosolic Ca and requirement for gene transcription[J]. J Mol Endocrinol, 2008,40(1):13-21.
[12] Vulpio C, Bossola M, Di Stasio E, et al. Intra-operative parathyroid hormone monitoring through central laboratory is accurate in renal secondary hyperparathyroidism[J]. Clin Biochem, 2016,49(7-8):538-543.
[13] 李珮婷, 李刚, 柳丽丹, 等. 继发性甲状旁腺功能亢进症来源的甲状旁腺原代细胞的培养及鉴定[J]. 南方医科大学学报, 2022,42(02):238-243.
[14] 孙海晨, 刘爽, 崔叶青, 等. 成人甲状旁腺细胞的培养方法及其分泌功能研究[J]. 中国普外基础与临床杂志, 2014,21(09):1120-1123.
[15] 赵越, 王晓辉, 刘爽, 等. 成人甲状旁腺细胞的培养和鉴定[J]. 中国普外基础与临床杂志, 2017,24(01):32-36.
[16] 王小兵, 王笑云, 毛慧娟, 等. 人甲状旁腺组织体外培养及高磷的影响[J]. 中华内分泌代谢杂志, 2006(01):79-80.
[17] Maqsood M I, Matin M M, Bahrami A R, et al. Immortality of cell lines: challenges and advantages of establishment[J]. Cell Biol Int, 2013,37(10):1038-1045.
[18] Dumont J, Euwart D, Mei B, et al. Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives[J]. Crit Rev Biotechnol, 2016,36(6):1110-1122.
[19] Liu N, Guo X H, Liu J P, et al. Role of telomerase in the tumour microenvironment[J]. Clin Exp Pharmacol Physiol, 2020,47(3):357-364.
[20] 黄今, 杨融辉, 马海英. 细胞永生化机制及不同细胞永生化方法研究进展[J]. 东南大学学报(医学版), 2015,34(05):821-824.
[21] Alwin P A A, Gowri S S, Kokila V V. Immortalization of neuronal progenitors using SV40 large T antigen and differentiation towards dopaminergic neurons[J]. J Cell Mol Med, 2012,16(11):2592-2610.
[22] Li P, Wu Y, Goodwin A J, et al. Generation of a new immortalized human lung pericyte cell line: a promising tool for human lung pericyte studies[J]. Lab Invest, 2021,101(5):625-635.
[23] Promjantuek W, Chaicharoenaudomrung N, Phonchai R, et al. Transgenic Immortalization of Human Dermal Fibroblasts Mediated Through the MicroRNA/SIRT1 Pathway[J]. In Vivo, 2022,36(1):140-152.
[24] Daya-Grosjean L, Azzarone B, Maunoury R, et al. SV40 immortalization of adult human mesenchymal cells from neuroretina. Biological, functional and molecular characterization[J]. Int J Cancer, 1984,33(3):319-329.
[25] Hung C J, Yao C L, Cheng F C, et al. Establishment of immortalized mesenchymal stromal cells with red fluorescence protein expression for in vivo transplantation and tracing in the rat model with traumatic brain injury[J]. Cytotherapy, 2010,12(4):455-465.
[26] Quarles L D. Extracellular calcium-sensing receptors in the parathyroid gland, kidney, and other tissues[J]. Curr Opin Nephrol Hypertens, 2003,12(4):349-355.
[27] Quarles L D. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease[J]. Kidney Int Suppl, 2005(96):S24-S28.
[28] Uchiyama T, Tatsumi N, Kamejima S, et al. Hypermethylation of the CaSR and VDR genes in the parathyroid glands in chronic kidney disease rats with high-phosphate diet[J]. Hum Cell, 2016,29(4):155-161.
[29] Lau W L, Obi Y, Kalantar-Zadeh K. Parathyroidectomy in the Management of Secondary Hyperparathyroidism[J]. Clin J Am Soc Nephrol, 2018,13(6):952-961.
[30] Canaff L, Guarnieri V, Kim Y, et al. Novel Glial Cells Missing-2 (GCM2) variants in parathyroid disorders[J]. Eur J Endocrinol, 2022,186(3):351-366.
[31] Yamada T, Tatsumi N, Anraku A, et al. Gcm2 regulates the maintenance of parathyroid cells in adult mice[J]. PLoS One, 2019,14(1):e210662.
[32] 练渝, 张玲, 杨阳, 等. 继发性甲状旁腺功能亢进症大鼠Gcm2的表达研究: 中华医学会第十二次全国内分泌学学术会议[C], 中国陕西西安, 2013.
